The concentration of heparin, an anticoagulant in blood, is usually inferred from clotting type assay, which determines a parameter related to the heparin activity. Because of the heterogeneity of heparin, however, it is desirable to monitor the absolute concentration of heparin directly in the clinical range of 0-2 U/ml. Surface plasmon resonance (SPR) provides a optical direct method of monitoring binding events. Gold films, as required for SPR, were modified with protamine; the immoblized protamine interacts electrostatically with heparin so that the heparin adsorption is dependent on the absolute concentration. The "thickness" of the immobilized protamine layer determined the linear range of the sensor's response and the sensitivity. Less densely packed layers of protamine showed a lower detection limit for heparin, suggesting a mixing of the heparin into the incomplete protamine layer. On the other hand, thicker, denser protamine layers did not show a low concentration sensitivity to heparin although their maximum heparin binding capacity was increased. It was shown that the linear response range of the protamine modified SPR device to heparin could be modulated by altering both the protamine loading and its method of immobilization. Copyright 1997 Academic Press. Copyright 1997Academic Press
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1006/jcis.1997.5097 | DOI Listing |
Ann Thorac Surg Short Rep
September 2024
HCA Healthcare Research Institute, HCA Healthcare, Nashville, Tennessee.
Background: Current treatment guidelines for infective endocarditis focus on left-sided infective endocarditis. Because right-sided infective endocarditis has different presentations and outcomes, it is crucial to further delineate surgical outcomes for isolated tricuspid valve endocarditis (TVE).
Methods: This retrospective study reviewed 374 surgically treated patients with isolated TVE from January 2012 through April 2022 who underwent isolated tricuspid valve surgical procedures.
Ann Thorac Surg Short Rep
September 2024
Division of Thoracic Surgery, Department of Surgery, Hackensack Meridian Health Network, Hackensack, New Jersey.
Background: In 2022, the American Association for Thoracic Surgery (AATS) and the European Society of Thoracic Surgeons (ESTS) published joint guidelines regarding the timing, duration, and choice of agent for perioperative venous thromboembolism prophylaxis for thoracic cancer patients. Now, 1 year after their release, we looked to assess practices and general adherence to these recommendations.
Methods: We conducted a survey among board-certified/board-eligible thoracic surgeons in the United States, between July and October 2023.
Adv Healthc Mater
January 2025
Department of Pharmaceutics, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.
Diabetic foot ulcer (DFU) is a common complication of chronic diabetes mellitus. Oxygen plays a critical role in the healing process of DFU wounds by promoting cell migration and neovascularization. However, clinical hyperbaric oxygen (HBO) therapy predominantly uses systemic oxygen administration, posing challenges in inadequate DFU local oxygen penetration and potential ectopic organs oxygen toxicity.
View Article and Find Full Text PDFIntroduction: Hemodialysis patients need long-term frequent use of parenteral anticoagulants, and the side effects need to be taken seriously. This study aimed to assess the reporting of adverse drug reactions (ADRs) following administration of unfractionated heparin (UFH), low molecular weight heparins (LMWHs), fondaparinux, and danaparoid, in relation to their usage in European Economic Area (EEA).
Materials And Methods: The total number of ADRs of each anticoagulant between 2017 to 2021 was collected using data from the EudraVigilance database.
Zhonghua Gan Zang Bing Za Zhi
December 2024
Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu61004, China.
To retrospectively analyze the dual plasma molecular adsorption system (DPMAS) treatment technology and the laboratory data before and after treatment in patients with liver failure and refractory hyperbilirubinemia, so as to provide a clinical basis for the prediction and prevention of common related complications. A retrospective study was conducted on 161 cases with liver failure and 68 cases with refractory hyperbilirubinemia who underwent DPMAS treatment in our department from October 2022 to July 2024. The general clinical data characteristics, DPMAS treatment status, DPMAS-related complications, and changes in important laboratory indicators before and after the initial DPMAS treatment in both patient groups were analyzed.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!